aTyr Pharma, Inc.

NasdaqCM:ATYR Stok Raporu

Piyasa değeri: US$42.2m

aTyr Pharma Yönetim

Yönetim kriter kontrolleri 2/4

aTyr Pharma CEO'su Sanjay Shukla, Nov2017 tarihinde atandı, in görev süresi 8.83 yıldır. in toplam yıllık tazminatı $ 3.46M olup, şirket hissesi ve opsiyonları dahil olmak üzere 18.5% maaş ve 81.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.16% ine doğrudan sahiptir ve bu hisseler $ 66.00K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.4 yıl ve 7.3 yıldır.

Anahtar bilgiler

Sanjay Shukla

İcra Kurulu Başkanı

US$3.5m

Toplam tazminat

CEO maaş yüzdesi18.49%
CEO görev süresi8.8yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi7.4yrs
Yönetim Kurulu ortalama görev süresi7.3yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Aug 14

Here's Why We're A Bit Worried About aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Apr 17

Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analiz Makalesi • Dec 18

Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analiz Makalesi • Mar 27

Will aTyr Pharma (NASDAQ:ATYR) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Sep 09

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

Summary Topline data from phase 3 EFZO-FIT study, using efzofitimod for the treatment of patients with pulmonary sarcoidosis, expected Q3 of 2025. The 7 major pulmonary sarcoidosis markets are expected to reach a value of $53.3 billion by 2034. Topline data from the phase 2 EFZO-CONNECT study, using efzofitimod for the treatment of patients with scleroderma-related ILD, expected Q2 of 2025. Several other competitors are creating their own drugs for pulmonary sarcoidosis, such as Novartis with CMK-389, Relief Therapeutics with RL-100, and Kinevant Sciences with Namilumab. Read the full article on Seeking Alpha
Analiz Makalesi • Jul 13

We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analiz Makalesi • Feb 03

We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analiz Makalesi • Oct 04

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analiz Makalesi • May 06

Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analiz Makalesi • Jan 04

We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 29

aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies

aTyr Pharma (NASDAQ:LIFE) said on Thursday the U.S. Patent and Trademark Office had issued a patent covering the company's methods for the use of anti-neuropilin-2 (NRP2) antibodies to treat cancer and inflammation. (LIFE) has risen ~6% before the bell. The blocking antibodies that aTyr has developed target distinct domains of NRP2, including those interacting with semaphorins, VEGF and certain chemokines.
Seeking Alpha • Sep 13

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

The U.S. Food and Drug Administration (FDA) granted fast track designation to aTyr Pharma's (NASDAQ:LIFE) lead drug candidate efzofitimod to treat systemic sclerosis (SSc, also known as scleroderma)-associated, interstitial lung disease (ILD). SSc is a progressive, autoimmune disease characterized by inflammation and scarring of connective tissues in the body. SSc which occurs in the lungs is called SSc-ILD. Clinical proof-of-concept was seen for efzofitimod in a phase 1b/2a trial in patients with pulmonary sarcoidosis, a form of ILD, the company said in a Sept. 13 press release. aTyr noted that it is currently investigating efzofitimod in patients with pulmonary sarcoidosis in a global phase 3 study called EFZO-FIT. The company added that it was the second fast track designation for efzofitimod clinical program and therapy had previously received the FDA's orphan drug designation for SSc LIFE +8.11% to $4.00 premarket Sept. 13
Seeking Alpha • Aug 11

aTyr Pharma gains with FDA Fast Track status for lead asset

The shares of clinical-stage biotech aTyr Pharma, Inc. (NASDAQ:LIFE) jumped ~7% in the pre-market Thursday after the company announced that the FDA issued Fast Track designation for its lead candidate efzofitimod for immune-mediated disease, pulmonary sarcoidosis. An immunomodulator, efzofitimod, is designed to downregulate humans' innate and adaptive immune responses. The candidate, also known as ATYR1923, is currently undergoing a global pivotal phase 3 study involving patients with pulmonary sarcoidosis. Sarcoidosis is a leading form of interstitial lung disease, and about 200K Americans are estimated to suffer from pulmonary sarcoidosis. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at severe conditions with unmet medical needs. It facilitates developers to conduct frequent communications with the regulator on plans for clinical studies. If certain criteria are met, such programs will also be able to win the Accelerated Approval, Priority Review, and Rolling Review, allowing the drugs to reach patients sooner.
Analiz Makalesi • May 10

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Jan 24

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 28

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

aTyr's lead candidate ATYR1923 recently came out with strong data in a proof of concept trial. Lead indication has a large market in the US. Company is early stage, but looks highly interesting.

CEO Tazminat Analizi

Sanjay Shukla'un ücretlendirmesi aTyr Pharma'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2026n/an/a

-US$61m

Mar 31 2026n/an/a

-US$70m

Dec 31 2025US$3mUS$639k

-US$74m

Sep 30 2025n/an/a

-US$75m

Jun 30 2025n/an/a

-US$67m

Mar 31 2025n/an/a

-US$63m

Dec 31 2024US$1mUS$581k

-US$64m

Sep 30 2024n/an/a

-US$64m

Jun 30 2024n/an/a

-US$58m

Mar 31 2024n/an/a

-US$54m

Dec 31 2023US$1mUS$561k

-US$50m

Sep 30 2023n/an/a

-US$43m

Jun 30 2023n/an/a

-US$45m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$2mUS$561k

-US$45m

Sep 30 2022n/an/a

-US$46m

Jun 30 2022n/an/a

-US$41m

Mar 31 2022n/an/a

-US$39m

Dec 31 2021US$2mUS$510k

-US$34m

Sep 30 2021n/an/a

-US$30m

Jun 30 2021n/an/a

-US$29m

Mar 31 2021n/an/a

-US$25m

Dec 31 2020US$1mUS$470k

-US$16m

Sep 30 2020n/an/a

-US$17m

Jun 30 2020n/an/a

-US$16m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$664kUS$450k

-US$24m

Tazminat ve Piyasa: Sanjay 'nin toplam tazminatı ($USD 3.46M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 652.98K ).

Tazminat ve Kazançlar: Sanjay şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Sanjay Shukla (54 yo)

8.8yrs
Görev süresi
US$3,456,253
Tazminat

Dr. Sanjay S. Shukla, M.D. M.S. has been the Chief Executive Officer, President and Director at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. fro...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Sanjay Shukla
President8.8yrsUS$3.46m0.16%
$ 66.0k
Jill Broadfoot
Chief Financial Officer8.2yrsUS$1.31m0.041%
$ 17.1k
Nancy E. Krueger
General Counsel & Corporate Secretary11.9yrsUS$1.28m0.036%
$ 15.3k
Ashlee Dunston
Director of Investor Relations & Corporate Communicationsno dataVeri yokVeri yok
Peter Villiger
Vice President of Corporate Development6.7yrsVeri yokVeri yok
Danielle Campbell
VP of Human Resource4.8yrsVeri yokVeri yok
Dalia Rayes
Head of Commercial1.5yrsVeri yokVeri yok
Leslie Nangle
Vice President of Researchno dataVeri yokVeri yok
7.4yrs
Ortalama Görev Süresi
58yo
Ortalama Yaş

Deneyimli Yönetim: ATYR 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.4 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Sanjay Shukla
President8.8yrsUS$3.46m0.16%
$ 66.0k
Eric Benevich
Independent Director1.8yrsUS$163.85k0%
$ 0
Sara Zaknoen
Independent Director5.3yrsUS$167.42k0.0061%
$ 2.6k
Timothy Coughlin
Independent Chairman of the Board9.4yrsUS$194.29k0.057%
$ 24.1k
Susan Ackerman
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Jane Gross
Independent Director7.3yrsUS$170.42k0.0099%
$ 4.2k
Svetlana Lucas
Independent Director7.3yrsUS$175.13k0.0061%
$ 2.6k
7.3yrs
Ortalama Görev Süresi
60yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: ATYR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/09/14 03:32
Gün Sonu Hisse Fiyatı2026/09/14 00:00
Kazançlar2026/06/30
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

aTyr Pharma, Inc. 19 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
James BirchenoughBMO Capital Markets Equity Research
Ilya ZubkovFreedom Broker
Vadim MerkulovFreedom Broker